[Chronic lymphocytic leukaemia].

Area of Science:

• Hematology
• Oncology
• Clinical Guidelines

Background:

• Chronic lymphocytic leukaemia (CLL) is the most prevalent leukaemia globally.
• CLL exhibits significant heterogeneity, with approximately 50% of patients never needing treatment.
• Standard treatment involves chemoimmunotherapy, with targeted therapies available for specific patient groups.

Purpose of the Study:

• To summarize current Danish guidelines for Chronic lymphocytic leukaemia (CLL) management.
• To review the efficacy of chemoimmunotherapy and targeted therapies in CLL.
• To highlight the continuous updating of guidelines based on clinical trial data.

Main Methods:

• Review of existing literature and clinical trial data.
• Analysis of current international and Danish CLL treatment guidelines.
• Synthesis of information on chemoimmunotherapy and targeted therapy effectiveness.

Main Results:

• Chemoimmunotherapy remains a standard treatment for CLL.
• Highly effective targeted therapies are approved for high-risk or relapsed CLL.
• Danish CLL guidelines are dynamically updated to incorporate new evidence.

Conclusions:

• Management of Chronic lymphocytic leukaemia (CLL) requires consideration of disease heterogeneity.
• Targeted therapies offer significant advancements for specific CLL patient populations.
• Adherence to updated clinical guidelines ensures optimal patient care in Denmark.